Compare UPBD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPBD | TSHA |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1996 | 2020 |
| Metric | UPBD | TSHA |
|---|---|---|
| Price | $17.94 | $4.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $32.25 | $10.56 |
| AVG Volume (30 Days) | 771.8K | ★ 2.1M |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | N/A | ★ 62.50 |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $4,695,061,000.00 | $8,333,000.00 |
| Revenue This Year | $6.30 | N/A |
| Revenue Next Year | $6.67 | N/A |
| P/E Ratio | $14.64 | ★ N/A |
| Revenue Growth | ★ 8.67 | N/A |
| 52 Week Low | $15.82 | $1.13 |
| 52 Week High | $28.03 | $6.02 |
| Indicator | UPBD | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 32.17 | 47.58 |
| Support Level | $17.18 | $4.41 |
| Resistance Level | $19.91 | $5.16 |
| Average True Range (ATR) | 0.88 | 0.20 |
| MACD | -0.44 | 0.00 |
| Stochastic Oscillator | 5.42 | 35.71 |
Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.